Compare FBDT & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBDT | COCH |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Blank Checks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 51.3M |
| IPO Year | 2026 | 2021 |
| Metric | FBDT | COCH |
|---|---|---|
| Price | $0.85 | $6.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 212.2K | 33.3K |
| Earning Date | 11-16-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $241,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.11 |
| 52 Week Low | $0.61 | $4.72 |
| 52 Week High | $1.25 | $47.70 |
| Indicator | FBDT | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 19.07 |
| Support Level | $0.73 | $4.72 |
| Resistance Level | $1.03 | $7.46 |
| Average True Range (ATR) | 0.08 | 0.41 |
| MACD | -0.01 | 0.93 |
| Stochastic Oscillator | 17.22 | 20.83 |
First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.